VolitionRx Announces First Peer-Reviewed Publication On Capture-Seq Liquid Biopsy Technology; Says It Is In Active Licensing Discussions Targeting $36B Combined MCED And MRD Market

Loading news article.

VolitionRx Announces First Peer-Reviewed Publication On Capture-Seq Liquid Biopsy Technology; Says It Is In Active Licensing Discussions Targeting $36B Combined MCED And MRD Market | WAPE

VolitionRx Announces First Peer-Reviewed Publication On Capture-Seq Liquid Biopsy Technology; Says It Is In Active Licensing Discussions Targeting $36B Combined MCED And MRD Market

Article summary

Related companies

Comments —